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Abstract: Cathepsin S (CatS) is a secreted cysteine protease that cleaves certain extracellular matrix
proteins, regulates antigen presentation in antigen-presenting cells (APC), and promotes M2-type
macrophage and dendritic cell polarization. CatS is overexpressed in many solid cancers, and overall,
it appears to promote an immune-suppressive and tumor-promoting microenvironment. While most
data suggest that CatS inhibition or knockdown promotes anti-cancer immunity, cell-specific inhibition,
especially in myeloid cells, appears to be important for therapeutic efficacy. This makes the design of
CatS selective inhibitors and their targeting to tumor-associated M2-type macrophages (TAM) and DC
an attractive therapeutic strategy compared to the use of non-selective immunosuppressive compounds
or untargeted approaches. The selective inhibition of CatS can be achieved through optimized small
molecule inhibitors that show good pharmacokinetic profiles and are orally bioavailable. The targeting
of these inhibitors to TAM is now more feasible using nanocarriers that are functionalized for a directed
delivery. This review discusses the role of CatS in the immunological tumor microenvironment and
upcoming possibilities for a nanocarrier-mediated delivery of potent and selective CatS inhibitors to
TAM and related APC to promote anti-tumor immunity.
Keywords: cysteine protease; cysteine cathepsin; nanoparticle; tumor microenvironment; immune
suppression; therapy; targeting; tumor associated macrophage; dendritic cell; T cell; antigen
presentation; antigen presenting cell; extracellular matrix (ECM); polarization; M2 macrophage;
tumor-associated macrophage (TAM)
1. Introduction
Intra- and extracellular protein degradation is central to the maintenance of homeostasis in health
and disease and therefore needs to be tightly controlled. Chronic diseases, especially autoimmunity,
organ fibrosis, and cancer are usually characterized by dysregulated proteolysis that contributes to
disease progression. The lysosomal proteases are involved in protein catabolism and some of them,
prominently several cysteine cathepsins, are overexpressed in tumors [1–3]. This makes them attractive
targets in the development of new anti-cancer drugs.
Cysteine cathepsins comprise a family of 11 proteases, of which 5 have been repeatedly
implicated in the progression of solid cancers (cathepsins B, H, K, L, and S) [4]. Among these,
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cathepsin S (CatS) has emerged as an attractive potential target whose inhibition promises to address
the immune-suppressive milieu of the tumor microenvironment (TME) [1,3,4] due to its role in
the polarization of antigen-presenting cells (APC) from an M1 toward a tumor-favoring M2-phenotype.
M2-type APC support myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages
(TAM), favoring the expansion of tolerogenic regulatory T cells (Treg) cells instead of cytotoxic CD8+ T
cells, which leads to an immune suppression in favor of tumor cells (Figure 1) [5].
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Figure 1. Role of cathepsin S (CatS) in the immune-suppressive milieu of the tumor microenvironment
(TME). (a) CatS is overexpressed in many tumors and favors the MHC-II pathway, leading to an increase
of CD4+ T cells instead of cytotoxic CD8+ T cells. (b) The inhibition of CatS can enhance the anti-tumor
immune response by promoting cytotoxic CD8+ T cells instead of CD4+ T cells [1,3].
In this review, the mechanisms of tumor promotion by cysteine cathepsins, with a focus on CatS
and its role in the TME, will be illustrated. Several inhibitors of CatS and strategies for efficient delivery
into the TME, mediated by nanoparticles, will be presented.
2. Cysteine Cathepsins in Tumor Progression
Cysteine cathepsins (Cat) are lysosomal proteases, usually with an activity optimum at an acidic
pH, that play an important role in intracellular protein catabolism. The cysteine cathepsins B, H,
K, L, and S are also excreted, partly tethered to the cell surface, where they also degrade certain
extracellular matrix (ECM) proteins. For CatS, these are several collagens, elastin, laminin-5, but
also cell surface receptors, such as protease-activated receptor-2, and cell adhesion molecules such
as junctional adhesion molecule B (JAM-B) and E-cadherin, which is an activity that facilitates tissue
remodeling, cancer cell growth, and spreading ([4] Table 1). The expression and activity of these
cathepsins is generally upregulated in (chronic) inflammation and in cancers. Consequently, they are
overexpressed in tumors, prominently for CatB and CatS, including in follicular lymphoma, gastric,
colon, brain, breast, and pancreatic cancer [1,3,6]. Overall, most but not all of these cathepsin-mediated
Cells 2020, 9, 2021 3 of 17
mechanisms result in enhanced ECM turnover and angiogenesis, clearing the way for tumor expansion,
securing the cancers’ nutrient supply, and, most notably, in suppressing the T-cell induced anti-cancer
immune response that is located in the TME. Here, cancer cells have developed mechanisms to escape
the surveillance of the immune system, both by limiting their (tumor) antigen presentation which
makes them “invisible” to the immune system and by their ability to actively condition their TME
by the secretion of factors that switch the non-tumor antigen-presenting cells (APC), mainly myeloid
cells and partly B cells, from an M1-type to an M2-type polarization. M1-type APC activate tumor
destroying CD8+ T cells, while M2-type APC induce tumor tolerogenic regulatory T cells (Treg) and
inactivate tumor destroying cytotoxic CD8+ T cells [3,7,8]. Here, the proteolytic activity of mainly
CatB and CatS, despite their complex regulation and diverse activities, has an overall disastrous effect
on anti-tumor immune responses by polarizing the myeloid APC in the TME from an M1-type toward
an M2-phenotype, favoring the expansion and suppressive function of myeloid-derived suppressor
cells (MDSC) and the related tumor-associated macrophages (TAM), resulting in the inactivation and
depletion of cytotoxic CD8+ T cells and the expansion of Treg [5]. CatS regulates antigen processing
and presentation, enhancing major histocompatibility class II (MHCII) expression and antigen loading
on myeloid endothelial and epithelial cells, including cancer epithelia. However, in contrast to antigen
presentation via MHC class I, prominently via (cancer) epithelial cells, that activate tumor cytotoxic
CD8+ T cells, MHCII presentation in the TME usually activates CD4+ Treg that actively suppress
cancer immunity [9–12]. Furthermore, a mouse model suggests that the CatS inhibition of Treg cells
may reduce the overall T-cell immunity under normal conditions, but it enhances the CD8+ T-cell
immunity in the presence of cancer cells [13]. Taken together, all these effects of CatS on cancer growth
make the inhibition of CatS an attractive strategy to limit tumor expansion and increase anti-tumor
immunogenicity [3,9–11].
Table 1. Cysteine cathepsins and their prominent roles in tumor progression.
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EC = endothelial cell; ECM = extracellular matrix; MDSC = myeloid-derived suppressor cells; IL-6 = interleukin 6;
COX2 = cyclooxygenase 2, CCL2 = CC-chemokine ligand-2; TAM = tumor-associated macrophage.
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Cathepsin S
Cathepsin S (CatS) is a papain-like two-domain protein that is synthesized in vivo as an inactive
precursor. Its propeptide is essential for the activation of the enzyme and proper folding [29,30].
The mature enzyme contains 217 residues with a catalytic Cys25 located in the active site and several
residues in the S1’–S3 pockets that determine the binding specificity for CatS among other papain-like
cysteine endopeptidases (Figure 2) [31,32].
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Figure 2. (a) Left: Cartoon model of the crystal structure of CatS in green (PDB 1MS6) in complex with
a covalent-reversible nitrile-based inhibitor in red bound covalently to the catalytic Cys25 of CatS. Right:
zoom into the active site of CatS with hydrogen bonds depicted in dashed lines. The subsites S1, S2, and
S3 are highlighted. (b) Domain structure of CatS. The residues that define the S1’–S3 pockets are listed
in the light gray box; residues that are the determinants of CatS binding specificity among papain-like
cysteine end peptidases are marked in red [32]. Figure 1a was prepared with MOE 2019.0102.
Although the different cathepsin subtypes have a high sequence homology, CatS differs from other
cysteine cathepsins by its stability at neutral pH and its limited tissue distribution with high levels found
in spleen and lung macrophages of healthy organisms [33,34]. CatS degrades the invariant chain that
occupies the MHCII binding pocket and promotes (tumor) antigen processing and their presentation
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to T cells via MHCII on APC [9]. However, as discussed above, this activates immune-suppressive
CD4+ Treg instead of tumor-destructive CD8+ T cells.
Recently, the effect of CatS inhibition in several experimental cancers has been demonstrated.
For instance, Da Costa et al. explored the inhibition of CatS in gastric cancer, where it is expressed
not only in the lysosomes but also secreted into the ECM. CatS silencing via small interfering RNA
(siRNA) led to a reduction of tumor volume and invasion accompanied by increased apoptosis and
attenuated angiogenesis [35,36]. Sevenich et al. claimed that CatS specifically mediates the blood–brain
barrier transmigration of breast cancer cells through proteolytic processing of the junctional adhesion
molecule B (JAM-B) and therefore, it plays an important role in brain metastasis [37]. Additionally,
Yang et al. showed that the increased expression of CatS correlates with the aggressiveness of human
colon cancer due to its promotion of the M2-type macrophage polarization (TAM), which is favored by
CatS-induced autophagy [38]. Moreover, preclinical studies by Burden et al. illustrate the impact of
inhibitory antibodies against CatS, resulting in an increased efficacy of chemotherapeutic treatments,
leading to a significant reduction of tumor growth [39,40]. Notably, CatS appears to play an important
role in liver cancer that is otherwise resistant to most conventional tumor therapies [41–43].
Bararia et al. reported an overexpression of CatS and its hyperactive mutant Y132D in follicular
lymphoma. The Y132D mutation results in a higher autocatalytic conversion from the inactive proform
to active CatS. In a CatS Y132D transgenic mouse model of follicular lymphoma, they observed
increased cancer growth versus wild-type controls and an increase of the tumor-suppressive CD4+ Treg
over cytotoxic CD8+ T cells infiltrating the tumor [1]. In confirmation, Dheilly et al. showed that in
patients with non-Hodgkin lymphoma, the same activating CatS Y132D mutation in malignant B cells
is promoted, and its inhibition abrogated lymphoma growth via enhancing the cytotoxic CD8+ T-cell
response and attenuating the expansion of CD4+ Treg [3]. Hence, the directed inhibition of CatS with
small molecule inhibitors could enhance the anti-tumor immune response in cancer, especially when
targeting the TME and the relevant APC, i.e., primarily myeloid TAM and MDSC, and—depending on
the tumor type—also B cells.
3. Cathepsin S Inhibitors
The search for selective CatS inhibitors dates back to the early 2000s and continues until today.
Some early reviews [44–47] cover the inhibition of cysteine proteases in general, while the first specific
compilation of selective CatS inhibitors appeared in 2004 [48]. CatS has a high sequence homology
with other Cathepsins (K, L, B), with some distinct differences in the S2 and S3 pockets which can be
addressed for selective CatS inhibition [32]. The S2 pocket of CatS contains Phe70, Gly137, Val162, Gly
165, and a flexible Phe211 located at the bottom of the pocket, which can lead to an open conformation
making space between itself and Phe70 and providing a possibility for pi-stacking interactions with
either or both phenylalanine residues [48]. In cathepsin K (CatK), Phe211 is replaced by Leu, making
the subsite tighter and more shallow. The two Gly residues in CatS are both Ala in Cat K and serve as
‘gatekeepers’. The missing methyl groups of the two Gly amino acids instead of Ala in CatS enable
the S2 pockets to be opened in width and in depth [32,49,50]. These differences make the search for
selective CatS inhibitors attractive, since the S2 pocket in CatS can be addressed by significantly lager
substituents compared to other cathepsins, e.g., CatK [49].
To date, there are over 1800 entries in the public access ZINC (ZINC is not commercial) database
regarding CatS inhibitors [51], most of them being non-selective and inhibiting other cathepsins as well.
The most selective and potent compounds developed for CatS inhibition comprise covalent as well as
non-covalent inhibitors [48,50,52]. Since the first investigated inhibitors for CatS, e.g., the pan-cathepsin
inhibitor LHVS (leucine homophenylalanine vinyl sulfone), contained an electrophilic warhead,
which bound to the catalytical cysteine residue in the active site of CatS in a covalent irreversible
mechanism, a wide variety of covalent reversible and interestingly also non-covalent inhibitors have
been developed [48]. This has opened up new possibilities in CatS inhibitor design. Most of the covalent
inhibitors contain a nitrile or an aldehyde as an electrophilic warhead, and the recognition sequence
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harbors either peptidic or non-peptidic residues. Both covalent and non-covalent inhibitors were
successfully co-crystallized with CatS (Figure 3) and many of those crystal structures are published
in the protein database (PDB) [53–58]. Since the latest reviews of CatS inhibitors covered the state of
research in CatS inhibitor design for the time between early 2000 to 2010, this paragraph focuses on
the progress made in the last decade [48,50,52].
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Figure 3. Overview of different non-covalent and covalent CatS-selective inhibitors from crystal
structures with compound ID and PDB (protein database) code of the corresponding crystal structure
(in parenthesis). The enzymatic data are given as either IC50 or Ki values [53–58].
One effort for optimizing the selectivity to ard atS via P2 substituents was done by Kerns et
al. reporting azepanone-based inhibitors (Figure 4) with 175-fold and 286-fold selectivity for CatS
versus CatK and CatL respectively [59]. The crucial modification in P2 with the introduction of
a 1-methyl-cyclohexyl alanine lead to compound 1 with an overall balanced potency and selectivity
profile. Another approach has been taken by Hilpert et al. through structure-based drug design starting
from a weakly active dual CatS/CatK inhibitor discovering a series of CatS-selective inhibitors that
contain different cyclic central scaffolds [57]. Out of the different tested scaffolds, a proline derivative
was identified as the most promising with IC50 values in the low nM range in enzymatic as well as
cell-based assays and a good ligand-binding efficiency (LE) of 0.47 (Figure 4) [57]. Another set of
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proline-derived compounds was synthesized and evaluated as CatS inhibitors by Kim et al., with
compound 3 (Figure 3) showing promising in vitro/in vivo pharmacological activities [60]. A known
bioavailable CatS nitrile inhibitor previously developed by Merck Frosst [49] was re-evaluated, and its
selective targeting of CatS over CatK/L/V and B was confirmed by an in vitro enzymatic assay. In vivo
experiments revealed that compound 4 could significantly reduce tumor volume in murine MC38
syngeneic and MCF7 xenograft models. Immunohistochemical analysis of MCF7 tumors revealed
that CatS inhibitor treatment with compound 4 significantly reduced proliferation and increased
apoptosis [61].
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Figure 4. Structures of five relevant CatS inhibitors discovered through SAR (structure–activity relation)
studies of the last decade.
Thus, this inhibitor may hold therapeutic potential and could be used to further analyze the role
of CatS in tumor development. One additional series of reversible CatS inhibitors consisting of
2,4,6-trisubstituted 1,3,5-triazines was synthesized and biologically evaluated by Tber et al., with
compound 5 being the most potent and selective inhibitor among the set, with an IC50 of 3 nM and
a Ki of 2 nM, respectively [62].
Overall, there has been progress in the field of CatS inhibitor research resulting in several potent
and selective compounds that have been developed in the last decade and that are suitable for the use
in further investigations focusing on the role that CatS plays in cancer and also other pathologies.
4. Nanocarrier-Mediated Delivery of Cathepsin Inhibitors
Despite pharmacodynamic target optimization, physicochemical parameters may sometimes
hamp r th in vivo translat bility of small molecular drugs, including some of the novel CatS inhibitors
discussed above. F r instance, poor solubility and reduce bioavailability might already pre nt them
from enter ng in vivo testings. Here, nan -sized carrier systems an provide un que opportunities
to alter t drugs’ pharmacokinetic profile and enhance their delivery to argeted sites of action. By
reventing premature release from the arrier or unwanted early m tabolic degradation, nano-sized
carrier systems can support the overall drug performance in vivo and at the same time reduce unwanted
side effects, which can further enable higher dosing, thus increasin the therapeut c w ndow [63].
Through the last four decades, nanocarriers have intense y been investi ated for the delivery
of classical a ti-cancer chemotherapeutics [64,65]. This has so far mostly been stimulated by
blood-circulating nanocarriers that can passively accumulate in highly vascularized tumors through
the enhanced permeability and retention (EPR) effect [66–68]. In parallel, several studies demonstrated
that nano-sized drug carriers also accumulate in lymphoid organs, such as the spleen, but also in the liver
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and lungs, as major first pass organs, to be rapidly taken up and processed by immune cells, in analogy to
classical pathogens of similar sizes, i.e., “the immune system likes nanotechnology” [69,70]. These more
recent insights have increased the interest in nanocarriers to assist in cancer immunotherapy [71–73].
Here, nanocarrier-mediated delivery of CatS inhibitors to focus their delivery to certain immune cells
in the tumor microenvironment, especially to TAM and MDSC, is an attractive approach.
Key criteria for precise delivery to specific immune cell populations include the carriers’
chemical composition, which should guarantee biocompatibility, biostability, and biointegrity
under physiological conditions. Moreover, toward clinical translatability, further issues including
biodegradability and clearance from the body must be taken into account as well. Consequently, these
characteristics needed for in vivo application exclude several nanocarriers that have been designed
throughout the last decades and claimed useful for drug delivery purposes [74]. So far, only a few
formulations passed phase 1–3 clinical trials and led to successful products on the market. Most
prolific amongst them are lipid formulation e.g., liposomal doxorubicine (Doxil) for solid tumors (e.g.,
breast or ovarian cancer), or the lately approved lipid-encapsulated siRNA formulation Patisiran [75].
Additionally, such formulations can be combined with polymer-based strategies, e.g., PEGylation
(poly(ethylene glycol) decoration) of liposomes or therapeutic proteins [76,77], which enable tissue
mobility and prolonged blood circulation.
Combining biocompatible hydrophilic polymers such as PEG and hydrophobic, self-assembling
block copolymers affords lipid-analogous polymer micelles with superior particle stabilities and drug
encapsulation capabilities [78]. As an example, South Korea approved a paclitaxel formulation using
PEG-block-poly-lactic-co-glycolic acid (PLGA) block copolymers (Genexol) [79]. Such systems support
the solubility of poorly water-soluble drugs by physiochemically entrapping them into the hydrophobic
domains of resulting nano-sized block copolymer self-assemblies.
PLGA has been approved by the FDA as synthetic hydrophobic copolymer and therefore, it
is frequently used for encapsulating therapeutically active molecules [80]. Consequently, similar
attempts have been made lately to encapsulate also cathepsin inhibitors, as recently summarized by
Prunk et al. [14] and Cogo et al. [81]. For instance, Kos et al. have encapsulated the endogenous
pan-cathepsin inhibitor cystatin, a 13.3 kDa protein, into PLGA microspheres and nanospheres via
a double emulsion process [82,83]. They also studied a biological polymer, chitosan, for cystatin
encapsulation via a gelation process including polyphosphates [84]. Similarly, the small molecule
hydroxyquinoline derivative nitroxoline, which exhibits CatB inhibitory activity, has more recently
been encapsulated into nanoparticles via gel-forming chitosan/chondroitin sulfate mixtures that further
allowed co-encapsulation of the anti-cancer agent 5-fluoruracil. [85] Other small molecule-based
cathepsin inhibitors could be co-formulated into polymeric nanoparticles, too. For instance, the group
of Schindeler locally delivered the CatK inhibitor L006235 encapsulated into PLGA nanospheres
together with recombinant human bone morphogenetic protein-2 (rhBMP-2) [86], while the group
of Prud’homme studied co-formulations of the CatK inhibitor odanacatib with the antifungal drug
itraconazole, which are both encapsulated into amphiphilic PEG-block-poly(styrene) nanocarriers [87].
Cathepsin inhibitor delivery has also been studied in liposomal formulations. In analogy to
the natural pan-cathepsin inhibitor cystatin, Mikhaylov et al. loaded the small molecule broad spectrum
inhibitor JPM-565 into PEGylated liposomes together with ferrimagnetic iron oxide nanoparticles
yielding “ferri-liposomes”, which allowed tumor-directed MRI-based imaging, and resulted in local
cathepsin inhibition and finally reduced mammary tumor growth [88]. Alternatively, in another study,
Mikhaylov et al. covalently attached the small molecule CatB inhibitor NS-629 to a DSPE-PEG (2000)
lipid and thus anchored it into the bilayer of resulting liposomes [89]. More lately, the same group
also applied this approach for the conjugation of the natural CatS and CatL inhibitor stefin A onto
the liposome surface, too [90].
Tabish et al. recently summarized further CatL inhibitors and proposed their delivery by
nanocarriers to enhance anti-tumor and antimetastatic activities [91]. As a recent example, Junior et al.
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reported the encapsulation of the CatL inhibitors Neq0551, Neq0554, and Neq0568 into protein-based
hollow ferritin nanocages and demonstrated improved drug delivery into cancer cells in vitro [92].
Taken together, such physicochemical encapsulation methods seem to be straightforward regarding
fabrication processes; however, several important challenges, including reproducible loading capacities,
avoiding premature drug release and controlled drug release at the target site need to be shown.
Especially, a chemically better defined and carefully designed approach to covalently link small molecule
drugs to the carrier may be promising. Here, the group of Kopecˇek synthesized well-defined conjugates
of the CatK inhibitor 1,5-bis (N-benzyloxy- carbonylleucyl) carbohydrazide with the water-soluble
hydrophilic polymers PEG and poly(2-hydroxypropyl methacrylamide) (HPMA) [93,94]. Yet, ligating
water-insoluble small molecules to hydrophilic polymers can stimulate less controlled inter- and
intramolecular self-assemblies that affect the nanocarriers’ integrity, especially under biologically
relevant conditions, e.g., by a less predictable adsorption of serum proteins [95,96].
To address these challenges, block copolymer micelles have been demonstrated to provide higher
drug-loading stability and carrier integrity when interchain cross-links are introduced, especially
into the hydrophobic core of the drug nanocarrier [97]. We have recently been following this
strategy [98] and optimized the nanocarriers for immunotherapeutic delivery (Figure 5) [99]. Via
covalent drug conjugation and hydrophilic core-crosslinking of self-assembled reactive ester block
copolymers, drug-loaded nanogels can be obtained with pH- or reductive-responsive degradation
profiles [100,101]. Interestingly, these carriers nicely facilitated the antiviral and antitumor immune
responses of highly potent small molecular Toll-like receptor 7/8 agonists [102–104]. Moreover, surface
chemistry modification can also be applied to further promote an active delivery of these carriers to
certain target immune cell subpopulations [105].
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To that respect, the targeted delivery of cathepsin inhibitors has also been followed by Kos et
al. by adsorbing anti-cytokeratin antibodies onto their cystatin-loaded PLGA nanosphere systems
to enhance delivery to breast cancer cells in vitro [106,107]. However, even more attractive for
the novel CatS inhibitors would be targeting their delivery to more relevant immune cells of
the TME, i.e., immune-suppressive TAM and MDSC [108,109]. Targeting these cell populations
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could so far be demonstrated for surface-modified reactive-ester based nanogels, either by using
polymers with α-mannosyl end groups binding to the overexpressed TAM mannose (MMR, CD206)
receptor in vitro [110] or by targeting this receptor through nanogel-conjugated MMR/CD206-binding
nanobodies in vivo [105]. The latter is currently considered to be more effective in terms of
cheap recombinant production and precise chemical modification compared to full antibodies
or antibody–drug conjugates. More recently, also peptide-based targeting strategies [111,112] or
multivalent mannose derivatives [113] have been exploited to guide nanoparticle delivery toward
TAM. Interestingly, mannose targeting has also been directly applied to small molecule cathepsin
inhibitors by generating glycoconjugates of monomannose, trimannose, and heptamannose with
the pan-cathepsin inhibitor DCG-04 [114].
Therefore, targeted delivery strategies of cathepsin inhibitors to immune-suppressive myeloid
cells, especially for CatS, create a highly promising approach to a novel anti-cancer treatment.
The nanocarrier-mediated delivery of CatS inhibitors has so far not been reported. Consequently,
based on the novel, highly specific CatS inhibitors and substantial advances in the development of
suitable nanocarriers that show promising performance not only in vitro but also in vivo, we expect
that combining both strategies has become an exciting research area for developing novel therapeutics
to sustainably suppress cancer growth and progression.
5. Conclusion and Outlook
The inhibition of tumor-associated cathepsins, especially cathepsin S (CatS), has emerged as a novel
promising strategy in cancer immunotherapy. CatS is prominently expressed in tumor associated
M2-type macrophages (TAM), dendritic cells (DC), and myeloid-derived suppressor cells (MDSC)
of the TME. Its inhibition downregulates MHC class II expression on TAM and DC, and repolarizes
TAM, DC, and MDSC toward the M1 phenotype that promotes the proliferation and activity of CD8+
tumor-destroying cytotoxic T cells, and that abrogates CD4+ immune-suppressive regulatory T cells. A
secondary effect is the suppression of tumor angiogenesis. Therefore, further research on CatS selective
inhibitors and their targeting to M2-type TAM, DC, and MDSC is warranted. We propose that selective
CatS inhibition by specific small molecule inhibitors or siRNA can be targeted to TAM, DC, and
MDSC via precisely modified nanocarriers equipped for the directed delivery and functional release of
the inhibitors. Such an approach provides novel opportunities for effective adjunctive therapies to
promote anti-tumor immunity.
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